stockportfolio.pro
AbCellera Biologics Inc. (ABCL)
Healthcare · Biotechnology · NasdaqGS
AbCellera Biologics Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.61M | $233.16M | $375.20M | $485.42M | $38.02M | $28.83M | $75.13M |
| Gross profit | — | — | — | $418.99M | $38.02M | $28.83M | — |
| Net income | $-2.21M | $118.92M | $153.46M | $158.52M | $-146.40M | $-162.86M | $-146.41M |
| Net margin | -19.0% | 51.0% | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
Source: AbCellera Biologics Inc. SEC filings (10-K).
Explore 7 years of AbCellera Biologics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ABCL in your portfolio →
AbCellera Biologics Inc. financial history by metric
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. — frequently asked questions
What is AbCellera Biologics Inc.'s revenue?
AbCellera Biologics Inc. (ABCL) reported revenue of $75.13M for fiscal year 2025, up 160.6% from the prior year, according to its SEC filings.
Is AbCellera Biologics Inc. profitable?
No — ABCL reported a net loss of $-146.41M in fiscal 2025.
What is ABCL's P/E ratio?
AbCellera Biologics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is AbCellera Biologics Inc. growing?
ABCL's revenue grew at roughly -20.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AbCellera Biologics Inc. have?
As of fiscal year 2025, ABCL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AbCellera Biologics Inc.'s market cap?
AbCellera Biologics Inc. (ABCL) has a market capitalization of about $1.57B, based on the latest data in our nightly-refreshed cache.
When does AbCellera Biologics Inc.'s fiscal year end?
ABCL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from AbCellera Biologics Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.